Skip to Content

Bisoprolol Fumarate

Class: beta-Adrenergic Blocking Agents
VA Class: CV100
Chemical Name: 2-Propanol, 1-(4-((2-(1-methylethoxy)ethoxy)methyl)phenoxy)-3-((1-methylethyl)amino),(±),(E)-2-butenedioate (2:1) (salt)
Molecular Formula: C18H31NO4•½C4H4O4
CAS Number: 104344-23-2
Brands: Zebeta

Medically reviewed by Drugs.com. Last updated on Feb 18, 2019.

Introduction

β1-selective adrenergic blocking agent (β-blocker).600 a

Uses for Bisoprolol Fumarate

Hypertension

Management of hypertension as monotherapy or in combination with other classes of antihypertensive agents.1 2 3 4 5 6 7 1200

β-Blockers generally not preferred for first-line therapy of hypertension according to current evidence-based hypertension guidelines, but may be considered in patients who have a compelling indication (e.g., prior MI, ischemic heart disease, heart failure) for their use or as add-on therapy in those who do not respond adequately to the preferred drug classes (ACE inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, or thiazide diuretics).67 501 502 503 504 515 523 524 527 800 1200 Bisoprolol is one of several β-blockers (including carvedilol, metoprolol succinate, metoprolol tartrate, nadolol, propranolol, and timolol) recommended by a 2017 ACC/AHA multidisciplinary hypertension guideline as first-line therapy for hypertension in patients with stable ischemic heart disease/angina.1200

Individualize choice of therapy; consider patient characteristics (e.g., age, ethnicity/race, comorbidities, cardiovascular risk) as well as drug-related factors (e.g., ease of administration, availability, adverse effects, cost).501 502 503 504 515 1200 1201

The 2017 ACC/AHA hypertension guideline classifies BP in adults into 4 categories: normal, elevated, stage 1 hypertension, and stage 2 hypertension.1200 (See Table 1.)

Source: Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13-115.

Individuals with SBP and DBP in 2 different categories (e.g., elevated SBP and normal DBP) should be designated as being in the higher BP category (i.e., elevated BP).

Table 1. ACC/AHA BP Classification in Adults1200

Category

SBP (mm Hg)

DBP (mm Hg)

Normal

<120

and

<80

Elevated

120–129

and

<80

Hypertension, Stage 1

130–139

or

80–89

Hypertension, Stage 2

≥140

or

≥90

The goal of hypertension management and prevention is to achieve and maintain optimal control of BP.1200 However, the BP thresholds used to define hypertension, the optimum BP threshold at which to initiate antihypertensive drug therapy, and the ideal target BP values remain controversial.501 503 504 505 506 507 508 515 523 526 530 1200 1201 1207 1209 1222 1223 1229

The 2017 ACC/AHA hypertension guideline generally recommends a target BP goal (i.e., BP to achieve with drug therapy and/or nonpharmacologic intervention) <130/80 mm Hg in all adults regardless of comorbidities or level of atherosclerotic cardiovascular disease (ASCVD) risk.1200 In addition, an SBP goal of <130 mm Hg generally is recommended for noninstitutionalized ambulatory patients ≥65 years of age with an average SBP of ≥130 mm Hg.1200 These BP goals are based upon clinical studies demonstrating continuing reduction of cardiovascular risk at progressively lower levels of SBP.1200 1202 1210

Other hypertension guidelines generally have based target BP goals on age and comorbidities.501 504 536 Guidelines such as those issued by the JNC 8 expert panel generally have targeted a BP goal of <140/90 mm Hg regardless of cardiovascular risk and have used higher BP thresholds and target BPs in elderly patients501 504 compared with those recommended by the 2017 ACC/AHA hypertension guideline.1200

Some clinicians continue to support previous target BPs recommended by JNC 8 due to concerns about the lack of generalizability of data from some clinical trials (e.g., SPRINT study) used to support the 2017 ACC/AHA hypertension guideline and potential harms (e.g., adverse drug effects, costs of therapy) versus benefits of BP lowering in patients at lower risk of cardiovascular disease.1222 1223 1224 1229

Consider potential benefits of hypertension management and drug cost, adverse effects, and risks associated with the use of multiple antihypertensive drugs when deciding a patient's BP treatment goal.1200 1220 1229

For decisions regarding when to initiate drug therapy (BP threshold), the 2017 ACC/AHA hypertension guideline incorporates underlying cardiovascular risk factors.1200 1207 ASCVD risk assessment is recommended by ACC/AHA for all adults with hypertension.1200

ACC/AHA currently recommend initiation of antihypertensive drug therapy in addition to lifestyle/behavioral modifications at an SBP ≥140 mm Hg or DBP ≥90 mm Hg in adults who have no history of cardiovascular disease (i.e., primary prevention) and a low ASCVD risk (10-year risk <10%).1200

For secondary prevention in adults with known cardiovascular disease or for primary prevention in those at higher risk for ASCVD (10-year risk ≥10%), ACC/AHA recommend initiation of antihypertensive drug therapy at an average SBP ≥130 mm Hg or an average DBP ≥80 mm Hg.1200

Adults with hypertension and diabetes mellitus, chronic kidney disease (CKD), or age ≥65 years are assumed to be at high risk for cardiovascular disease; ACC/AHA state that such patients should have antihypertensive drug therapy initiated at a BP ≥130/80 mm Hg.1200 Individualize drug therapy in patients with hypertension and underlying cardiovascular or other risk factors.502 1200

In stage 1 hypertension, experts state that it is reasonable to initiate drug therapy using the stepped-care approach in which one drug is initiated and titrated and other drugs are added sequentially to achieve the target BP.1200 Initiation of antihypertensive therapy with 2 first-line agents from different pharmacologic classes recommended in adults with stage 2 hypertension and average BP >20/10 mm Hg above BP goal.1200

Black hypertensive patients generally tend to respond better to monotherapy with calcium-channel blockers or thiazide diuretics than to β-blockers.45 53 54 501 504 1200 However, diminished response to β-blockers is largely eliminated when administered concomitantly with a thiazide diuretic.500

Heart Failure

Management of mild to moderately severe (NYHA class II or III) heart failure of ischemic or cardiomyopathic origin in conjunction with other heart failure therapies (e.g., cardiac glycosides, diuretics, ACE inhibitors).23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 524 800

The American College of Cardiology Foundation (ACCF), AHA, and the Heart Failure Society of America (HFSA) recommend therapy with an ACE inhibitor, angiotensin II receptor antagonist, or angiotensin receptor-neprilysin inhibitor (ARNI) in conjunction with a β-blocker, and an aldosterone antagonist in selected patients, to reduce morbidity and mortality in patients with symptomatic heart failure and reduced left ventricular ejection fraction (LVEF) (ACCF/AHA stage C heart failure).800

Initiate a clinical-trial proven β-blocker (bisoprolol, carvedilol, extended-release metoprolol succinate) to reduce the risk of death in patients with chronic heart failure; benefits shown with these β-blockers not considered indicative of a β-blocker class effect.524

Experts recommend that β-blockers also be used in conjunction with ACE inhibitors in all patients who have asymptomatic heart failure (i.e., structural heart disease but no signs or symptoms; ACCF/AHA stage B heart failure) with reduced LVEF.524 800

Bisoprolol Fumarate Dosage and Administration

General

  • Individualize dosage according to patient response and tolerance.3 18

  • If long-term therapy is discontinued, reduce dosage gradually over a period of about 1–2 weeks.1 2 20 (See Abrupt Withdrawal of Therapy under Cautions.)

BP Monitoring and Treatment Goals

  • Monitor BP regularly (i.e., monthly) during therapy and adjust dosage of the antihypertensive drug until BP controlled.1200

  • If unacceptable adverse effects occur, discontinue drug and initiate another antihypertensive agent from a different pharmacologic class.1216

  • If adequate BP response not achieved with a single antihypertensive agent, either increase dosage of single drug or add a second drug with demonstrated benefit and preferably a complementary mechanism of action (e.g., ACE inhibitor, angiotensin II receptor antagonist, calcium-channel blocker, thiazide diuretic).1200 1216 Many patients will require ≥2 drugs from different pharmacologic classes to achieve BP goal; if goal BP still not achieved, add a third drug.1200 1216

Administration

Oral Administration

Administer orally;1 2 3 4 5 6 7 absorption does not appear to be affected by food.1 2 3 4 6 7

Dosage

Available as bisoprolol fumarate; dosage expressed in terms of the fumarate.1 2 3

Pediatric Patients

Hypertension
Bisoprolol/Hydrochlorothiazide Fixed-combination Therapy
Oral

Some experts have recommended an initial dosage of 2.5 mg of bisoprolol fumarate and 6.25 mg of hydrochlorothiazide daily.52 If needed, dosage may be increased to 10 mg of bisoprolol fumarate and 6.25 mg of hydrochlorothiazide once daily.52

Adults

Hypertension
Bisoprolol Therapy
Oral

Initially, 2.5–5 mg once daily.1 3 5 18 21

May increase dosage gradually, generally at intervals of ≥2 weeks,3 18 based on BP response up to maximum of 20 mg daily.1 2 3 18

Some experts state usual dosage range is 2.5–10 mg once daily.1200

Bisoprolol/Hydrochlorothiazide Fixed-combination Therapy
Oral

Patients in whom BP is not adequately controlled by monotherapy with bisoprolol fumarate 2.5–20 mg daily or those who respond adequately to a hydrochlorothiazide dosage of 50 mg daily but experience problematic potassium loss can switch to a fixed-combination preparation containing bisoprolol and hydrochlorothiazide.2 3

Can use the fixed combination as a substitute for the individually titrated drugs.600

Alternatively, may initiate antihypertensive therapy with the fixed-combination preparation containing bisoprolol fumarate 2.5 mg and hydrochlorothiazide 6.25 mg daily.2 3

Heart Failure
Oral

Initially, 1.25 mg daily40 for 2–4 weeks or less suggested in adults with mild to moderately severe heart failure.22 30 524

If tolerated, increase to 2.5 mg daily for 2–4 weeks; subsequent dosages can be doubled every 2–4 weeks.22 30

If deterioration (usually transient) occurs during titration, increase dosage of concurrent diuretic40 524 and decrease dosage of β-blocker or temporarily discontinue β-blocker as appropriate.524 Do not continue dosage titration until symptoms of worsening heart failure have stabilized.524 Initial difficulty in dosage titration should not preclude subsequent attempts to successfully titrate the dosage.40

Reduce dosage in patients with heart failure who experience symptomatic bradycardia (e.g., dizziness) or 2nd or 3rd degree heart block.524

Prescribing Limits

Pediatric Patients

Hypertension
Bisoprolol/Hydrochlorothiazide Fixed-combination Therapy
Oral

Some experts have stated that the maximum dosage is 10 mg of bisoprolol fumarate and 6.25 mg of hydrochlorothiazide daily.52

Adults

Hypertension
Bisoprolol Therapy
Oral

Maximum is 20 mg daily.1 2 3

Bisoprolol/Hydrochlorothiazide Fixed-combination Therapy
Oral

Dosage generally should not exceed bisoprolol fumarate 20 mg and hydrochlorothiazide 12.5 mg daily.2 3

Heart Failure
Oral

Maximum dosage recommended by ACCF and AHA: 10 mg once daily.524

Special Populations

Hepatic Impairment

Hepatitis or cirrhosis: Initially 2.5 mg once daily.1 Increase dosage with caution.1 3

Renal Impairment

Clcr <40 mL/minute: Initially 2.5 mg daily.1 Increase dosage with caution.1 3

Clcr <20 mL/minute per 1.73 m2: Generally, maximum 10 mg once daily.4 6 8 a

Hemodialysis: Apparently not removed by dialysis; supplemental dose is not required after dialysis;3

Bisoprolol/hydrochlorothiazide fixed combination: Discontinue if progressive renal impairment develops.2

Geriatric Patients

Dosage adjustment not required unless appreciable renal or hepatic impairment is present.1 2

Bronchospastic Disease

Initially, 2.5 mg daily;1 3 use the possible lowest dosage.1

Cautions for Bisoprolol Fumarate

Contraindications

  • Patients with sinus bradycardia, heart block greater than first degree, cardiogenic shock, or overt heart failure.1 2

  • Hypersensitivity to bisoprolol fumarate, any ingredient in the formulation, or sulfonamides.2

Warnings/Precautions

Warnings

Heart Failure

Possible precipitation of heart failure.1 2

Avoid use in overt heart failure;1 2 may use cautiously in patients with well-compensated heart failure (e.g., those controlled with cardiac glycosides and/or diuretics).1 2

Adequate treatment (e.g., with a cardiac glycoside and/or diuretic) and close observation recommended if signs or symptoms of impending heart failure occur; if heart failure continues, discontinue therapy, gradually if possible.1 2 22 40

Abrupt Withdrawal of Therapy

Abrupt discontinuance of therapy is not recommended as it may exacerbate symptoms or precipitate MI or ventricular arrhythmias in patients with CAD.1 2 Gradually decrease dosage over 1–2 weeks and monitor patients carefully.1 2 3 19 20 If manifestations of withdrawal (exacerbation of angina or hypotension) occur, increase dosage or reinstitute therapy, at least temporarily.1 2 3

Peripheral Vascular Disease

Possible precipitation or aggravation of symptoms of arterial insufficiency; use with caution.1 2

Bronchospastic Disease

Generally should not be used in patients with bronchospastic disease,1 2 but may be used with caution in such patients who do not respond to or cannot tolerate alternative treatment.1 2

Administer the lowest effective dosage (initially 2.5 mg once daily);1 2 a bronchodilator (e.g. a β2-adrenergic agonist) should be available.1 2

Major Surgery

Use with caution in patients undergoing major surgery involving general anesthesia.1 2 Use particular care if anesthetics that depress the myocardium (e.g., cyclopropane, ether, trichloroethylene) are used.1 2 (See Specific Drugs under Interactions.)

Diabetes and Hypoglycemia

Possible decreased signs and symptoms of hypoglycemia (e.g., tachycardia).1 2

Use with caution in patients with diabetes mellitus receiving hypoglycemic drugs.1 2

Thyrotoxicosis

Signs of hyperthyroidism (e.g., tachycardia) may be masked.1 2 Possible exacerbation of hyperthyroidism or precipitation of thyroid storm if therapy is abruptly withdrawn; carefully monitor patients having or suspected of developing thyrotoxicosis.1 2

General Precautions

History of Anaphylactic Reactions

Possible increased reactivity to repeated, accidental, diagnostic, or therapeutic challenges with a variety of allergens while taking β-blockers.1 2 Such patients may be unresponsive to usual doses of epinephrine.1 2

Other Precautions

Shares the toxic potentials of β-blockers; observe the usual precautions of these agents.1 2 In addition, when used in fixed-combination with hydrochlorothiazide, consider the cautions, precautions, and contraindications associated with thiazide diuretics.1 2

Specific Populations

Pregnancy

Category C.1 2

Lactation

Not known whether bisoprolol fumarate is distributed into human milk.1 2 Use with caution.1

Pediatric Use

Safety and efficacy not established in children;1 2 however, some experts have recommended the use of bisoprolol fumarate/hydrochlorothiazide fixed combination in hypertensive children (1–17 years of age).52

Geriatric Use

Safety and efficacy profiles in geriatric individuals are similar to those in younger adults.1 2

Hepatic Impairment

In patients with hepatitis or cirrhosis, reduce initial dosage and adjust dosage cautiously.1 3 (See Hepatic Impairment under Dosage and Administration.)

Renal Impairment

Clcr <40 mL/minute: Threefold increase in half-life;1 2 reduce initial dosage and adjust dosage cautiously.1 3 (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Fatigue, headache, diarrhea, peripheral edema, and upper respiratory tract infection.1 2

Interactions for Bisoprolol Fumarate

Not metabolized by isoenzyme CYP2D6.

Specific Drugs

Drug

Interaction

Comments

β-Blockers

Do not use with other β- blockers1 2

Catecholamine-depleting drugs (e.g., reserpine, guanethidine)

Possible additive effects with concurrent use1 2

Monitor closely for excessive decreases in sympathetic activity1 2

Calcium-channel blocking agents (e.g., verapamil, diltiazem])

Potential for additive negative effects on AV nodal conduction

Use with caution1 2

Cimetidine

No clinically important pharmacokinetic interaction1 2

Clonidine

β-Adrenergic blockade may exacerbate rebound hypertension which may occur following clonidine discontinuance a

Discontinue β-blockers several days before withdrawal of clonidine 1 2

Digoxin

No clinically important pharmacokinetic interaction

Disopyramide

Potential for additive negative effects on AV nodal conduction1 2

Use with caution1 2

Myocardial depressant general anesthetics (e.g., ether, cyclopropane, trichloroethylene)

Increased risk of hypotension and heart failure1 2

Use with caution1 2 41

Rifampin

Potential for increased clearance and decreased elimination half-life of bisoprolol1 2

Initial dosage adjustments of bisoprolol are not necessary1 2

Thiazide diuretics

No clinically important pharmacokinetic interaction1 2

Warfarin

No effect on prothrombin time with stable warfarin dosage1 2

Bisoprolol Fumarate Pharmacokinetics

Absorption

Bioavailability

About 80%.1 2

Onset

In healthy individuals, decreased tachycardia (exercise- and isoproterenol-induced) occurs within 1–4 hours.1 2

Duration

In normal individuals, decreased tachycardia generally persists for 24 hours.1 2

Food

Food does not appear to affect absorption.1

Distribution

Extent

Not known whether distributed into human milk.1 2

Plasma Protein Binding

About 30%.1 2

Elimination

Metabolism

Not metabolized by CYP2D6.1 2

20% first-pass metabolism.1 2

Elimination Route

Excreted in urine as unchanged drug (50%) and as inactive metabolites; less than 2% excreted in feces.1 2

Half-life

9–12 hours.1 2

Special Populations

In patients with cirrhosis, half-life is more variable and substantially prolonged (range: 8.3–21.7 hours).1 2

In renal impairment (Clcr <40 mL/minute), threefold increase in half-life.1 (See Renal Impairment under Dosage and Administration.)

In geriatrics, half-life slightly increased due to decreased renal function.1 2

Stability

Storage

Oral

Tablets

Tight containers at 20–25°C.1

Tablets (Bisoprolol Fumarate and Hydrochlorothiazide)

Tight containers at 20–25°C.2

Actions

  • Inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium.1 Blocks β2-adrenergic receptors within the bronchial and vascular smooth muscle only at high doses.1 2 3 4 7

  • Decreases resting and exercise-stimulated heart rate and cardiac output, decreases isoproterenol-induced tachycardia, prolongs sinus node recovery time, refractory period of the AV node, and AV nodal conduction (with rapid atrial stimulation).1 2

  • No intrinsic sympathomimetic activity or membrane-stabilizing effect on the heart.1 2

  • Reduces blood pressure by decreasing cardiac output, decreasing sympathetic outflow from the CNS, and or suppressing renin release.1 2

Advice to Patients

  • Importance of taking medication exactly as prescribed.1

  • Importance of not interrupting or discontinuing therapy without consulting clinician.1 2

  • Importance of informing clinician at the first sign or symptom of heart failure, excessive bradycardia, or if any difficulty in breathing occurs.1 2

  • Importance of informing anesthesiologist or dentist that they are receiving bisoprolol therapy prior to undergoing major surgery.1 2

  • Importance of informing patients with diabetes that the drug may mask signs and symptoms of hypoglycemia, including increased heart rate.1 2

  • Importance of avoiding some activities (e.g., operating machinery or driving a motor vehicle or those requiring mental alertness).1 2

  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs.1 2

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1 2

  • Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Bisoprolol Fumarate

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

5 mg*

Bisoprolol Fumarate Tablets

Zebeta (scored)

Barr

10 mg*

Bisoprolol Fumarate Tablets

Zebeta

Barr

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Bisoprolol Fumarate and Hydrochlorothiazide

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Tablets, film-coated

2.5 mg with Hydrochlorothiazide 6.25 mg*

Bisoprolol Fumarate and Hydrochlorothiazide Tablets

Ziac

Barr

5 mg with Hydrochlorothiazide 6.25 mg*

Bisoprolol Fumarate and Hydrochlorothiazide Tablets

Ziac

Barr

10 mg with Hydrochlorothiazide 6.25 mg*

Bisoprolol Fumarate and Hydrochlorothiazide Tablets

Ziac

Barr

AHFS DI Essentials™. © Copyright 2019, Selected Revisions February 18, 2019. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Lederle Pharmaceutical. Zebeta (bisoprolol fumarate) tablets prescribing information. Pearl River, NY; 2001 Dec.

2. Lederle Pharmaceutical. Ziac (bisoprolol fumarate and hydrochlorothiazide) tablets prescribing information. Pearl River, NY; 2001 Apr 3.

3. Lederle Laboratories. Product information summary on Ziac and Zebeta. Pearl River, NY; 1993 May.

4. Lancaster SG, Sorkin EM. Bisoprolol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris. Drugs. 1988; 36:256-85. http://www.ncbi.nlm.nih.gov/pubmed/2903820?dopt=AbstractPlus

5. Boeijinga JK, Van Zwienen JCW, Schmitz PIM et al. A dose-finding study with bisoprolol in the treatment of mild tomoderate essential hypertension. Curr Ther Res. 1990; 48: 1036-43.

6. Steinwandt SM, Abadi AH, Rutledge DR. Focus on bisoprolol: a once-daily beta blocker providing 24-hour blood pressure control with balanced renal and hepatic elimination. Hosp Formul. 1993; 28:453-64.

7. Prichard BNC. Bisoprolol: a new beta-adrenoceptor blocking drug. Eur Heart J. 1987; 8(Suppl M):121-9.

8. Kirch W, Rose I, Demers HG et al. Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease. Clin Pharmacokinet. 1987; 13:110-7. http://www.ncbi.nlm.nih.gov/pubmed/2887325?dopt=AbstractPlus

10. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1984; 26:107-12. http://www.ncbi.nlm.nih.gov/pubmed/6150424?dopt=AbstractPlus

12. Haeusler G, Shliep HJ, Schelling P et al. High β1-in selectivity and favourable pharmacokinetics as the outstanding properties of bisoprolol. J Cardiovasc Pharmacol. 1986; 8(Suppl 11):S2-15. http://www.ncbi.nlm.nih.gov/pubmed/2439793?dopt=AbstractPlus

13. Cuthbert MF, Owusu-Ankomah K. Effect of M&B 17803A, a new β-adrenoceptor blocking agent, on the cardiovascular responses to tilting and to isoprenaline in man. Br J Pharmacol. 1971; 43:639-48. http://www.ncbi.nlm.nih.gov/pubmed/4400530?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=1665788&blobtype=pdf

14. Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976; 19:203-4. http://www.ncbi.nlm.nih.gov/pubmed/10600?dopt=AbstractPlus

15. Weiner N. Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Gilman AG, Goodman LS, Rall TW et al, eds. Goodman and Gilman’s the pharmacologic basis of therapeutics. 7th ed. New York: Macmillan Publishing Company; 1985:181-214.

16. Mimnaugh MW, Gearien JE. Adrenergic drugs. In: Foye WE, ed. Principles of medicinal chemistry. 2nd ed. Philadelphia: Lea and Febiger; 1981:377-93.

17. Machin PJ, Jurst DN, Bradshaw RW et al. β-Selective adrenoceptor antagonists.Part 2: 4-ether-linked phenoxypropanolamines. J Med Chem. 1983; 26:1570-6. http://www.ncbi.nlm.nih.gov/pubmed/6138435?dopt=AbstractPlus

18. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153:154-83. http://www.ncbi.nlm.nih.gov/pubmed/8422206?dopt=AbstractPlus

19. Anon. Drugs for hypertension. Med Lett Drugs Ther. 1993; 35:55-60. http://www.ncbi.nlm.nih.gov/pubmed/8099706?dopt=AbstractPlus

20. Lederle Laboratories, Pearl River, NY: Personal communication.

21. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Bethesda, MD: National Institutes of Health; 1997 Nov. (NIH publication No. 98-4080.)

22. Anon. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Part II. Management of heart failure: approaches to the prevention of heart heart failure (MERIT-HF). Am J Cardiol. 1999; 83:9-38A.

23. Packer M, Colucci WS, Sackner-Bernstein JD et al, for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation. 1996; 94:2793-9.

24. Fisher ML, Gottlieb SS, Plotnick GD et al. Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol. 1994; 23:943-50. http://www.ncbi.nlm.nih.gov/pubmed/8106700?dopt=AbstractPlus

25. Bristow MR, Gilbert EM, Abraham WT et al, for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996; 94:2807-16.

26. Metra M, Nardi M, Raffaele G et al. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in paatients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1994; 24:1678-87. http://www.ncbi.nlm.nih.gov/pubmed/7963115?dopt=AbstractPlus

27. Olsen SL, Gilbert EM, renlund DG et al. Carvedilol improves left ventricular function and symptoms in chronic heart failre: a double-blind randomized study. J Am Coll Cardiol. 1995; 25:1225-31. http://www.ncbi.nlm.nih.gov/pubmed/7722114?dopt=AbstractPlus

28. Krum H, Sackner-Bernstein JD, Goldsmith RL et al. Double-blind placebo controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation. 1995; 92:1499-506. http://www.ncbi.nlm.nih.gov/pubmed/7664433?dopt=AbstractPlus

29. Waagstein F, Bristow MR, Swedberg K et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet. 1993; 342:1441-6. http://www.ncbi.nlm.nih.gov/pubmed/7902479?dopt=AbstractPlus

30. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation. 1990; 90:1765-73.

31. Colucci WS, Packer M, Bristow MR et al, for the US Carvedilol Heart Failure Study Group. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996; 94:2800-6.

32. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353:2001-7. http://www.ncbi.nlm.nih.gov/pubmed/10376614?dopt=AbstractPlus

33. Bristow MR, Gilbert EM, Abraham WT et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardimyopathy. Circulation. 1996; 94(Suppl I):I664.

34. Lechat P, Packer M, Chalon S et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation. 1998; 98:1184-91. http://www.ncbi.nlm.nih.gov/pubmed/9743509?dopt=AbstractPlus

35. Van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: an analysis of studies published in the literature. J Cardiovasc Pharmacol. 1998; 32(Suppl 1):S31-5. http://www.ncbi.nlm.nih.gov/pubmed/9731693?dopt=AbstractPlus

36. SmithKline Beecham Pharmaceuticals. Coreg (carvedilol) tablets prescribing information. Philadelphia, PA; 1998 May.

37. Rousseau MF, Chapelle F, Van Eyll C et al. Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail. 1996; 2:15-23. http://www.ncbi.nlm.nih.gov/pubmed/8798100?dopt=AbstractPlus

38. Mattioli AV, Modena MG, Fantini G et al. Atenolol in dilated cardiomyopathy: a clinical instrumental study. Cardiovasc Drugs Ther. 1990; 4:505-7. http://www.ncbi.nlm.nih.gov/pubmed/2285633?dopt=AbstractPlus

39. Califf RM, O’Connor CM. β-Blocker therapy for heart failure. The evidence is in, now the work begins. JAMA. 2000; 283:1335-6. http://www.ncbi.nlm.nih.gov/pubmed/10714735?dopt=AbstractPlus

40. Hunt SA, Baker DW, Chin MH et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. Available from website. Accessed July 25, 2002. http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards.aspx

41. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). JAMA. 2000; 283:1295-1302. http://www.ncbi.nlm.nih.gov/pubmed/10714728?dopt=AbstractPlus

42. Appel LJ. The verdict from ALLHAT—thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002; 288:3039-42. http://www.ncbi.nlm.nih.gov/pubmed/12479770?dopt=AbstractPlus

43. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288:2981-97. http://www.ncbi.nlm.nih.gov/pubmed/12479763?dopt=AbstractPlus

45. Douglas JG, Bakris GL, Epstein M et al. Management of high blood pressure in African Americans: Consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003; 163:525-41.

47. The Guidelines Subcommitee of the WHO/ISH Mild Hypertension Liaison Committee. 1999 guidelines for the management of hypertension. J Hypertension. 1999; 17:392-403.

48. Izzo JL, Levy D, Black HR. Importance of systolic blood pressure in older Americans. Hypertension. 2000; 35:1021-4. http://www.ncbi.nlm.nih.gov/pubmed/10818056?dopt=AbstractPlus

49. Frohlich ED. Recognition of systolic hypertension for hypertension. Hypertension. 2000; 35:1019-20. http://www.ncbi.nlm.nih.gov/pubmed/10818055?dopt=AbstractPlus

50. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000; 36:646-61. http://www.ncbi.nlm.nih.gov/pubmed/10977801?dopt=AbstractPlus

52. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004; 114(Suppl 2):555-76. http://www.ncbi.nlm.nih.gov/pubmed/15286277?dopt=AbstractPlus

53. Wright JT, Dunn JK, Cutler JA et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293:1595-607. http://www.ncbi.nlm.nih.gov/pubmed/15811979?dopt=AbstractPlus

54. Neaton JD, Kuller LH. Diuretics are color blind. JAMA. 2005; 293:1663-6. http://www.ncbi.nlm.nih.gov/pubmed/15811986?dopt=AbstractPlus

56. Thadani U. Beta blockers in hypertension. Am J Cardiol. 1983; 52:10-5D.

57. Shand DG. State-of-the-art: comparative pharmacology of the β-adrenoceptor blocking drugs. Drugs. 1983; 25(Suppl 2):92-9.

58. Breckenridge A. Which beta blocker? Br Med J. 1983; 286:1085-8.

59. Anon. Choice of a beta-blocker. Med Lett Drugs Ther. 1986; 28:20-2. http://www.ncbi.nlm.nih.gov/pubmed/2869400?dopt=AbstractPlus

60. Wallin JD, Shah SV. β-Adrenergic blocking agents in the treatment of hypertension: choices based on pharmacological properties and patient characteristics. Arch Intern Med. 1987; 147:654-9. http://www.ncbi.nlm.nih.gov/pubmed/2881524?dopt=AbstractPlus

61. McDevitt DG. β-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs. 1983; 25:331-8.

62. McDevitt DG. Clinical significance of cardioselectivity: state-of-the-art. Drugs. 1983; 25(Suppl 2):219-26.

63. Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981; 305:500-6. http://www.ncbi.nlm.nih.gov/pubmed/6114433?dopt=AbstractPlus

64. Thadani U, Davidson C, Chir B et al. Comparison of the immediate effects of five β-adrenoceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979; 300:750-5. http://www.ncbi.nlm.nih.gov/pubmed/581782?dopt=AbstractPlus

65. Lewis RV, McDevitt DG. Adverse reactions and interactions with β-adrenoceptor blocking drugs. Med Toxicol. 1986; 1:343-61. http://www.ncbi.nlm.nih.gov/pubmed/2878346?dopt=AbstractPlus

66. Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987; 113:1190-8. http://www.ncbi.nlm.nih.gov/pubmed/2883867?dopt=AbstractPlus

67. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.

500. National Heart, Lung, and Blood Institute National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). Bethesda, MD: National Institutes of Health; 2004 Aug. (NIH publication No. 04-5230.)

501. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507-20. http://www.ncbi.nlm.nih.gov/pubmed/24352797?dopt=AbstractPlus

502. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31:1281-357. http://www.ncbi.nlm.nih.gov/pubmed/23817082?dopt=AbstractPlus

503. Go AS, Bauman MA, Coleman King SM et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014; 63:878-85. http://www.ncbi.nlm.nih.gov/pubmed/24243703?dopt=AbstractPlus

504. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich). 2014; 16:14-26. http://www.ncbi.nlm.nih.gov/pubmed/24341872?dopt=AbstractPlus

505. Wright JT, Fine LJ, Lackland DT et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med. 2014; 160:499-503. http://www.ncbi.nlm.nih.gov/pubmed/24424788?dopt=AbstractPlus

506. Mitka M. Groups spar over new hypertension guidelines. JAMA. 2014; 311:663-4. http://www.ncbi.nlm.nih.gov/pubmed/24549531?dopt=AbstractPlus

507. Peterson ED, Gaziano JM, Greenland P. Recommendations for treating hypertension: what are the right goals and purposes?. JAMA. 2014; 311:474-6. http://www.ncbi.nlm.nih.gov/pubmed/24352710?dopt=AbstractPlus

508. Bauchner H, Fontanarosa PB, Golub RM. Updated guidelines for management of high blood pressure: recommendations, review, and responsibility. JAMA. 2014; 311:477-8. http://www.ncbi.nlm.nih.gov/pubmed/24352759?dopt=AbstractPlus

515. Thomas G, Shishehbor M, Brill D et al. New hypertension guidelines: one size fits most?. Cleve Clin J Med. 2014; 81:178-88. http://www.ncbi.nlm.nih.gov/pubmed/24591473?dopt=AbstractPlus

523. Fihn SD, Gardin JM, Abrams J et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012; 126:e354-471.

524. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128:e240-327.

526. Kernan WN, Ovbiagele B, Black HR et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014; :. http://www.ncbi.nlm.nih.gov/pubmed/24788967?dopt=AbstractPlus

527. O'Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013; 127:e362-425. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3695607&blobtype=pdf

530. Myers MG, Tobe SW. A Canadian perspective on the Eighth Joint National Committee (JNC 8) hypertension guidelines. J Clin Hypertens (Greenwich). 2014; 16:246-8. http://www.ncbi.nlm.nih.gov/pubmed/24641124?dopt=AbstractPlus

536. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012: 2: 337-414.

600. Duramed Pharmaceuticals, Inc. Ziac (bisoprolol fumarate and hydrochlorothiazide) tablets prescribing information. Pomona, NY; 2011 Mar.

701. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; :. http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4946749&blobtype=pdf

702. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371:993-1004. http://www.ncbi.nlm.nih.gov/pubmed/25176015?dopt=AbstractPlus

703. Ansara AJ, Kolanczyk DM, Koehler JM. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck. J Clin Pharm Ther. 2016; 41:119-27. http://www.ncbi.nlm.nih.gov/pubmed/26992459?dopt=AbstractPlus

707. Amgen Inc. Corlanor (ivabradine) tablets prescribing information. Thousand Oaks, CA; 2015 Apr.

708. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010; 376:875-85. http://www.ncbi.nlm.nih.gov/pubmed/20801500?dopt=AbstractPlus

709. Urbanek I, Kaczmarek K, Cygankiewicz I et al. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014; 6:47-54. http://www.ncbi.nlm.nih.gov/pubmed/24855390?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4010635&blobtype=pdf

710. Di Franco A, Sarullo FM, Salerno Y et al. Beta-blockers and ivabradine in chronic heart failure: from clinical trials to clinical practice. Am J Cardiovasc Drugs. 2014; 14:101-10. http://www.ncbi.nlm.nih.gov/pubmed/24327100?dopt=AbstractPlus

711. Schuster A, Tang WH. Ivabradine in heart failure: to SHIFT or not to SHIFT. Curr Heart Fail Rep. 2011; 8:1-3. http://www.ncbi.nlm.nih.gov/pubmed/21057902?dopt=AbstractPlus

712. Borer JS, Böhm M, Ford I et al. Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study. Eur Heart J. 2012; 33:2813-20. http://www.ncbi.nlm.nih.gov/pubmed/22927555?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=3498004&blobtype=pdf

800. Yancy CW, Jessup M, Bozkurt B et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016; :.

1200. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:el13-e115. http://www.ncbi.nlm.nih.gov/pubmed/29133356?dopt=AbstractPlus

1201. Bakris G, Sorrentino M. Redefining hypertension - assessing the new blood-pressure guidelines. N Engl J Med. 2018; 378:497-499. http://www.ncbi.nlm.nih.gov/pubmed/29341841?dopt=AbstractPlus

1202. Carey RM, Whelton PK, 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018; 168:351-358. http://www.ncbi.nlm.nih.gov/pubmed/29357392?dopt=AbstractPlus

1207. Burnier M, Oparil S, Narkiewicz K et al. New 2017 American Heart Association and American College of Cardiology guideline for hypertension in the adults: major paradigm shifts, but will they help to fight against the hypertension disease burden?. Blood Press. 2018; 27:62-65. http://www.ncbi.nlm.nih.gov/pubmed/29447001?dopt=AbstractPlus

1209. Qaseem A, Wilt TJ, Rich R et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2017; 166:430-437. http://www.ncbi.nlm.nih.gov/pubmed/28135725?dopt=AbstractPlus

1210. SPRINT Research Group, Wright JT, Williamson JD et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. http://www.ncbi.nlm.nih.gov/pubmed/26551272?dopt=AbstractPlus

1216. Taler SJ. Initial treatment of hypertension. N Engl J Med. 2018; 378:636-644. http://www.ncbi.nlm.nih.gov/pubmed/29443671?dopt=AbstractPlus

1220. Cifu AS, Davis AM. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 2017; 318:2132-2134. http://www.ncbi.nlm.nih.gov/pubmed/29159416?dopt=AbstractPlus

1222. Bell KJL, Doust J, Glasziou P. Incremental benefits and harms of the 2017 American College of Cardiology/American Heart Association high blood pressure guideline. JAMA Intern Med. 2018; 178:755-7. http://www.ncbi.nlm.nih.gov/pubmed/29710197?dopt=AbstractPlus

1223. LeFevre M. ACC/AHA hypertension guideline: what is new? what do we do?. Am Fam Physician. 2018; 97(6):372-3. http://www.ncbi.nlm.nih.gov/pubmed/29671534%20?dopt=AbstractPlus

1224. Brett AS. New hypertension guideline is released. From NEJM Journal Watch website. Accessed 2018 Jun 18. https://www.jwatch.org/na45778/2017/12/28/nejm-journal-watch-general-medicine-year-review-2017

1229. Ioannidis JPA. Diagnosis and treatment of hypertension in the 2017 ACC/AHA guidelines and in the real world. JAMA. 2018; 319(2):115-6. http://www.ncbi.nlm.nih.gov/pubmed/29242891?dopt=AbstractPlus

1235. Mann SJ. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens. 2017; 11(1):54-65. http://www.ncbi.nlm.nih.gov/pubmed/28057444?dopt=AbstractPlus

a. AHFS Drug Information 2019. McEvoy GK, ed. Bisoprolol. American Society of Health-System Pharmacists; 2019:.

Hide